Literature DB >> 32232486

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

Fabienne Lucas1,2, Karylin Larkin1,2, C Thomas Gregory1,2, Shelley Orwick1,2, Tzyy-Jye Doong1,2, Arletta Lozanski1,2, Gerard Lozanski3, Shrilekha Misra1,2, Apollinaire Ngankeu1,2, Hatice Gulcin Ozer4, Deepa Sampath1,2, Shanmugapriya Thangavadivel1,2, Selen A Yilmaz4, Kerry A Rogers1,2, John C Byrd1,2,5,6, Jennifer A Woyach1,2,5, James S Blachly1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32232486      PMCID： PMC7290091          DOI： 10.1182/blood.2019003722

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors:  Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Cancer Discov       Date:  2018-12-04       Impact factor: 39.397

2.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

3.  Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.

Authors:  Eugen Tausch; William Close; Anna Dolnik; Johannes Bloehdorn; Brenda Chyla; Lars Bullinger; Hartmut Döhner; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

4.  Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Authors:  Piers Blombery; Ella R Thompson; Tamia Nguyen; Richard W Birkinshaw; Jia-Nan Gong; Xiangting Chen; Michelle McBean; Rachel Thijssen; Thomas Conway; Mary Ann Anderson; John F Seymour; David A Westerman; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Blood       Date:  2020-03-05       Impact factor: 22.113

5.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

Authors:  Vicente Fresquet; Melissa Rieger; Carlo Carolis; Maria J García-Barchino; Jose A Martinez-Climent
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

6.  Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  John F Seymour; Thomas J Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; John Gerecitano; Tadeusz Robak; Javier De la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Rod Humerickhouse; Elizabeth A Punnoose; Yan Li; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Arnon P Kater
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

7.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Authors:  Jeffrey A Jones; Anthony R Mato; William G Wierda; Matthew S Davids; Michael Choi; Bruce D Cheson; Richard R Furman; Nicole Lamanna; Paul M Barr; Lang Zhou; Brenda Chyla; Ahmed Hamed Salem; Maria Verdugo; Rod A Humerickhouse; Jalaja Potluri; Steven Coutre; Jennifer Woyach; John C Byrd
Journal:  Lancet Oncol       Date:  2017-12-12       Impact factor: 41.316

8.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; Amy S Ruppert; Daphne Guinn; Amy Lehman; James S Blachly; Arletta Lozanski; Nyla A Heerema; Weiqiang Zhao; Joshua Coleman; Daniel Jones; Lynne Abruzzo; Amber Gordon; Rose Mantel; Lisa L Smith; Samantha McWhorter; Melanie Davis; Tzyy-Jye Doong; Fan Ny; Margaret Lucas; Weihong Chase; Jeffrey A Jones; Joseph M Flynn; Kami Maddocks; Kerry Rogers; Samantha Jaglowski; Leslie A Andritsos; Farrukh T Awan; Kristie A Blum; Michael R Grever; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 50.717

9.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Authors:  Carmen D Herling; Nima Abedpour; Jonathan Weiss; Anna Schmitt; Ron Daniel Jachimowicz; Olaf Merkel; Maria Cartolano; Sebastian Oberbeck; Petra Mayer; Valeska Berg; Daniel Thomalla; Nadine Kutsch; Marius Stiefelhagen; Paula Cramer; Clemens-Martin Wendtner; Thorsten Persigehl; Andreas Saleh; Janine Altmüller; Peter Nürnberg; Christian Pallasch; Viktor Achter; Ulrich Lang; Barbara Eichhorst; Roberta Castiglione; Stephan C Schäfer; Reinhard Büttner; Karl-Anton Kreuzer; Hans Christian Reinhardt; Michael Hallek; Lukas P Frenzel; Martin Peifer
Journal:  Nat Commun       Date:  2018-02-20       Impact factor: 14.919
  9 in total
  5 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR.

Authors:  Biqin Tan; Rong Dong; Bo Zhang; Youyou Yan; Qingyu Li; Fei Wang; Nengming Lin
Journal:  Cancer Cell Int       Date:  2020-09-17       Impact factor: 5.722

Review 3.  Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.

Authors:  Thomas E Lew; John F Seymour
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

4.  High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.

Authors:  Emanuela M Ghia; Laura Z Rassenti; Michael Y Choi; Miguel Quijada-Álamo; Elvin Chu; George F Widhopf; Thomas J Kipps
Journal:  Leukemia       Date:  2022-04-13       Impact factor: 12.883

Review 5.  Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.

Authors:  Yvonne J Thus; Eric Eldering; Arnon P Kater; Marcel Spaargaren
Journal:  Leukemia       Date:  2022-06-20       Impact factor: 12.883
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.